Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Allenamento oculomotorio perimetrico dello scotoma (SPOT)

25 settembre 2026 aggiornato da: Kristina M Visscher, University of Alabama at Birmingham

Nuovi metodi per quantificare e addestrare le strategie di movimento oculare nella degenerazione maculare

The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function and preservation of sight.

Declines in vision are particularly common in older adults and thus increasing our understanding of how to cre- ate effective means of improving vision is also highly relevant to the mission of the NIA to support research on aging and the health and well-being of older people.

Panoramica dello studio

Descrizione dettagliata

This proposal tests a novel 'scotoma awareness' approach to aid those with Macular Degeneration (MD). MD is the leading cause of central vision loss worldwide. MD patients spontaneously develop oculomotor strategies to overcome loss of central vision, such as developing a new peripheral fixation spot to replace the fovea (preferred retinal locus, or PRL). However, development of a PRL and the rate of success in developing one vary greatly, meaning some patients live years without making effective use of their spared vision. Recent, studies in Vision Science show that training healthy participants with gaze-contingent displays, obstructing central vision ('simulated scotoma'), leads to development of PRLs at a faster time scale than found for MD patients. Additionally, oculomotor metrics developed in our lab, are effective in characterizing individual eye movement patterns in simulated scotoma participants. The ability to describe differences in compensatory strategies in MD represents a crucial step towards individualized rehabilitative strategies, which could be further improved by accelerating PRL development. However, it is unclear whether these results can be reproduced in those with MD. It has been suggested that the visible, sharp-edged occluder in the gaze- contingent displays increases scotoma awareness, thus accelerating PRL development. Many MD patients are unaware of the location of their scotoma, with some persisting to use their damaged fovea as a fixation spot. No study to date has translated the use of a simulated scotoma to promote rapid PRL development in MD patients. As a first step towards addressing individual differences in patients and examine whether Vision Science paradigms can be used as a rehabilitative tool in MD, we propose two Aims: In Aim 1 we will use a set of oculomotor metrics to characterize individual profiles of compensation. In Aim 2 we will test the effectiveness of the visible, simulated scotoma as a technique to promote the rapid development of a PRL. Patients will undergo a 'scotoma awareness' training, in which a simulated scotoma, individually tailored for each patient, will be used to help them visualize their region of vision loss. Patients will be tested on the same metrics from Aim 1 and a battery of visual and cognitive assessments before and after the 'scotoma awareness' (or control) sessions. This will enable quantification of the effect of scotoma awareness both in terms of visual abilities and oculomotor strategies, and test the hypothesis that awareness of the location and extent of retinal damage promotes fast PRL development. While challenging, the use of eye tracking techniques in patients could be highly rewarding if this scotoma awareness procedure proves to be effective. A null result would be equally informative, suggesting fundamental differences between physiological and simulated scotomas, thus providing a limit in the use of simulations of retinal damage as a framework for the study of retinal pathologies such as MD. This will provide a unique data set to help those developing interventions for central vision loss understand how approaches to visual rehabilitation, and individual differences, give rise to training outcomes.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

21

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35294
        • UAB

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 89 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Severely impaired vision in both eyes (20/100 or worse)
  • Diagnosis of Macular Degeneration
  • Light sensitivity in the macular retina that is at least 10 dB units worse than in peripheral regions, as demonstrated by a scanning laser ophthalmoscope (SLO, MAIA)
  • Medical record review indicates this disease severity level has been present for at least 2 years.

Exclusion Criteria:

  • Inability to sit still in eye tracker for extended periods
  • Inability to visualize iris on video eye tracker
  • Bilateral retinal scotomas larger than 20° diameter

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Condition 1 - 'Scotoma awareness' Training

Participants will be asked to report the emotion of an emoji face ('happy' vs 'sad') that could appear anywhere on screen. For the entire duration of the training, an explicit, sharp outlined occluder surrounding the participant's true retinal scotoma will be rendered on screen. This occluder will be generated through a gaze-contingent display. The size and the contrast of the target will change adaptively in response to the patient's performance.

In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.

Sperimentale: Condition 2 - Control Training

In the control condition, participants will perform the same task as the scotoma awareness training, without the artificial visible scotoma.

The task will be performed in the control group without the visible scotoma.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline Fixation Stability After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Dispersion of fixation locations averaged across trials in which the participant used their PRL (expressed as the Bivariate contour ellipse area (BCEA) of the dispersion of fixation locations).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Visual Acuity After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Score of Change in baseline visual acuity, in logMAR units after training. Measured as post-test minus pre-test.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Saccadic Re-referencing After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Proportion of trials with first fixation using PRL (expressed as a % of the total number of trials). Expressed as post-test minus pre-test.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline First Saccade Landing Dispersion After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

The dispersion of the end point of the first saccade (expressed as the Bivariate contour ellipse area, BCEA of the dispersion). BCEA is the area (in deg^2) of an ellipse encompassing the fixation points, as described by Crossland et al., 2011.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Latency of Target Acquisition After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

The mean time until target is visible outside scotoma (expressed in seconds).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Saccadic Precision After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

The dispersion of the end point of the saccade that puts the target outside scotoma (expressed as the BCEA of the dispersion).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Percentage of Trials That Are Useful After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

How often participants place the target outside of the scotoma (% of dots in Saccadic precision relative to total trials). Definition of "trials that are useful" is that the target is placed outside the scotoma at some point during the trial.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Minimal Print Size From MNREAD Task After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

For the MNREAD test we will primarily rely upon minimal print size (a secondary measure of acuity). MNREAD is a computerized version of the task from Mansfield et al., 1993 from Gordon Legge's lab. Participants perform the task without any simulated scotoma. Sentences are shown to participants in a standardized order, from largest to smallest. The words are read out loud. The task stops when the participant can no longer read the sentence. The number of sentences is thus a measure of how small the print can be for a participant to read it effectively. Larger number of sentences is a better minimal print size. Thus we expect that effective training will result in greater values at post-test than at baseline.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Time-to-complete Trailmaking B Subtest After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

We will look at time-to-complete the Trail Making B subtest, measured in seconds. Post-test minus baseline. Trailmaking B test is often thought of as a measure of executive function. The task requires ordering numbers and letters, and switching between them (e.g., Find 1, then A, then 2, then B, then 3... etc.).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Contrast Sensitivity After Completion of Training at Approximately 6 Weeks and 14 Weeks
Lasso di tempo: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Measured via Robson-Pelli charts. Contrast sensitivity is a measure of what visual contrast the participant can detect. This outcome is in units of log contrast sensitivity

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 novembre 2022

Completamento primario (Effettivo)

4 giugno 2025

Completamento dello studio (Effettivo)

30 giugno 2025

Date di iscrizione allo studio

Primo inviato

7 luglio 2022

Primo inviato che soddisfa i criteri di controllo qualità

12 luglio 2022

Primo Inserito (Effettivo)

13 luglio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 settembre 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Results of the project will be submitted to the relevant repository (ClinicalTrials.gov, or Open-Science Framework) within one year of the final participant completing data collection. We expect to report participant flow by group (intervention or control), participant demographics and other baseline characteristics, outcome measures and statistical analyses, adverse events (if applicable), and limitations or caveats of our results. We also will ensure that the final protocol and statistical analysis plan are uploaded to the record.

Periodo di condivisione IPD

Results of the project will be submitted to the relevant repository (ClinicalTrials.gov, or Open-Science Framework) within one year of the final participant completing data collection.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • CODICE_ANALITICO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi